Loading clinical trials...

Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Advanced Esophageal Cancer | Clinical Trials | Clareo Health

UNKNOWN

Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Advanced Esophageal Cancer

Containing Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Anti-tumor Treatment of Chinese Patients With Unresectable Locally Advanced / Recurrent or Metastatic Esophageal Cancer: a Real World Study

NCT05349045•The First Affiliated Hospital of Zhengzhou University

View on ClinicalTrials.gov

Summary

The combination of an anti-PD-1/PD-L1 antibody with an angiogenesis inhibitor has shown efficacy in many cancers.The purpose of this study is to confirm that the combination of these two drugs can benefit patients with advanced esophageal cancer.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Esophageal cancer confirmed by histopathology or cytology
•2. Unresectable locally advanced/recurrent or metastatic esophageal cancer, or progression after neoadjuvant or adjuvant therapy
•3. Esophageal cancer patients who benefit from the use of an anti-PD-1/PD-L1 antibody with an angiogenesis inhibitor evaluated by the researchers
•4. Patients who sign informed consent and voluntarily join the study

Exclusion Criteria

•1. Patients who are recommended not using an anti-PD-1/PD-L1 antibody or an angiogenesis inhibitor in the instructions, or other patients who are judged by the investigators to be unsuitable in the study
•2. Patients who are undergoing treatment regimen of blind trial

Locations (1)

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China

Key Dates

Start Date

May 5, 2022

Primary Completion Date

May 5, 2024

Completion Date

May 5, 2025

Last Updated

April 27, 2022

Enrollment

300

ESTIMATED participants

Conditions

Esophageal Neoplasms

Interventions

an anti-PD-1/PD-L1 antibody plus an angiogenesis inhibitor

DRUG

Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis Techniques

NCT07035587

Lung NeoplasmsPancreatic Neoplasms+6 more

View study

RECRUITING

Barrett's Esophagus and Esophageal Adenocarcinoma, Searching for Reliable Diagnostic RNA Plasma-based Biomarkers

NCT05688176

Esophageal Neoplasms

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 27, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Advanced Esophageal Cancer

Inclusion Criteria

Exclusion Criteria

Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis Techniques

Barrett's Esophagus and Esophageal Adenocarcinoma, Searching for Reliable Diagnostic RNA Plasma-based Biomarkers

Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.

Esophageal Cancer Multimodal Prehabilitation Study

A Liquid Biopsy for High-risk Pre-cancer Screening of Esophageal Adenocarcinoma

KCNA3 and OTOP2 Gene Methylation Combined Detection Kit (Fluorescent PCR Method)